

1 **Thermal cycling protects SH-SY5Y cells against**  
2 **hydrogen peroxide and  $\beta$ -amyloid-induced cell injury**  
3 **through stress response mechanisms involving Akt**  
4 **pathway**

5

6

7 Wei-Ting Chen<sup>1,2,¶</sup>, Yu-Yi Kuo<sup>1,2,¶</sup>, Guan-Bo Lin<sup>1,2,¶</sup>, Chueh-Hsuan Lu<sup>1,2</sup>,  
8 Hao-Ping Hsu<sup>3</sup>, Yi-Kun Sun<sup>2</sup>, and Chih-Yu Chao<sup>1,2,4,\*</sup>

9

10 <sup>1</sup> Department of Physics, Lab for Medical Physics & Biomedical Engineering, National  
11 Taiwan University, Taipei 10617, Taiwan

12 <sup>2</sup> Biomedical & Molecular Imaging Center, National Taiwan University College of  
13 Medicine, Taipei 10051, Taiwan

14 <sup>3</sup> Department of Medicine, National Taiwan University College of Medicine, Taipei  
15 10051, Taiwan

16 <sup>4</sup> Graduate Institute of Applied Physics, Biophysics Division, National Taiwan  
17 University, Taipei 10617, Taiwan

18

19 \* Corresponding author

20 E-mail: cychao@phys.ntu.edu.tw (CYC)

21 ¶ These authors contributed equally to this work.

22

## 23 **Abstract**

24 Neurodegenerative diseases (NDDs) are becoming a major threat to public health,  
25 according to the World Health Organization (WHO). The most common form of  
26 NDDs is Alzheimer's disease (AD), boasting 60-70% share. Although some debates  
27 still exist, excessive aggregation of  $\beta$ -amyloid protein ( $A\beta$ ) and neurofibrillary tangles  
28 has been deemed one of the major causes for the pathogenesis of AD. A growing  
29 number of evidences from studies, however, have suggested that reactive oxygen  
30 species (ROS) also play a key role in the onset and progression of AD. Although  
31 scientists have had some understanding of the pathogenesis of AD, the disease still  
32 cannot be cured, with existing treatment only capable of providing a temporary relief  
33 at best, partly due to the obstacle of blood-brain barrier (BBB). The study was aimed  
34 to ascertain the neuroprotective effect of thermal cycle hyperthermia (TC-HT) against  
35 hydrogen peroxide ( $H_2O_2$ ) and  $A\beta$ -induced cytotoxicity in SH-SY5Y cells. Treating  
36 cells with this physical stimulation beforehand significantly improved the cell  
37 viability and decreased the ROS content. The underlying mechanisms may be due to  
38 the activation of Akt pathway and the downstream antioxidant and prosurvival  
39 proteins. The findings manifest significant potential of TC-HT in neuroprotection, via  
40 inhibition of oxidative stress and cell apoptosis. It is believed that coupled with the  
41 use of drugs or natural compounds, this methodology can be even more effective in

42 treating NDDs.

43

## 44 **Introduction**

45 According to the World Health Organization (WHO), the number of  
46 dementia-induced deaths more than doubled between 2000 and 2016, making it the  
47 5th leading cause for deaths worldwide in 2016, up from 14th place in 2000. Among  
48 the various forms of dementia such as Alzheimer's disease (AD) and Parkinson's  
49 disease (PD), AD is the most common one, accounting for 60–70% of the cases.  
50 Typically, AD exhibits such features as deposition of cortical plaques caused by  
51 excessive aggregation of  $\beta$ -amyloid protein ( $A\beta$ ) and neurofibrillary tangles, and  
52 progressive brain degeneration and deterioration of cognitive function among elderly  
53 people. Although the exact mechanism of AD pathogenesis remains unknown, it is  
54 believed that oxidative stress and activation of free radicals, induced by  $A\beta$   
55 aggregation, play a key role in AD pathogenesis [1].

56 Reactive oxygen species (ROS) are reactive chemical species containing oxygen,  
57 which are generated as natural byproduct of oxygen metabolism. ROS play important  
58 roles in cell signalling and homeostasis, and their concentrations in cells are subtly  
59 regulated by various antioxidant compounds and enzymes. However, with cells under  
60 continuing environmental stress (e.g. ultraviolet, inflammatory cytokines, or

61 environmental toxins), the imbalance between prooxidants and antioxidants may  
62 cause chronic oxidative stress. Accumulation of ROS may cause cell death, accelerate  
63 cell ageing, or induce age-related diseases [2]. More and more research evidences  
64 have suggested that ROS plays a central role in the onset and progression of AD [3].  
65 Therefore, the protection of neural cells against oxidative damage may be a potential  
66 strategy to treat AD. Several in vitro or in vivo studies have explored the function of  
67 antioxidant and antiapoptotic drugs in ameliorating AD [4-6] but the approach is  
68 time-consuming and costly, plus the safety concern, which limits the use of these  
69 drugs in AD treatment. Moreover, the blood-brain barrier (BBB) dampens the efficacy  
70 of these drugs, since over 98% of small molecule drugs and ~100% of large molecule  
71 drugs can not pass the BBB [7]. Therefore, a non-drug treatment may be more suited  
72 to AD patients.

73 Scientists have long been interested in the profound effects of heat on cells, and  
74 have utilized it in various types of thermotherapeutical applications such as  
75 physiotherapy, urology, and cardiology [8]. One promising and effective thermal  
76 therapy is the treatment of cancer by hyperthermia (HT) [9]. HT is used to kill cancer  
77 cells directly or to potentiate the cytotoxicity of radiation and certain chemotherapy  
78 drugs [10]. The ROS level increased by HT treatment has been identified to play an  
79 important role as an intracellular mediator of HT-induced cell death [11]. On the

80 contrary, it has also been reported that heat shock (HS) will induce many cellular  
81 defense, including the antioxidant effect. For example, Tchouagué *et al* demonstrated  
82 that HS-generated ROS is involved in induction of cellular defense molecules Prxs,  
83 GSH and G6PD through Nrf2 activation [12]. Mustafi *et al* also showed that heat  
84 stress upregulates the HSP70 and MnSOD levels through ROS and p38MAPK [13].  
85 In addition to the thermal treatment, the beneficial effects of light treatment were also  
86 reported in literatures. The review article by Hamblin summarized some pre-clinical  
87 studies and clinical trials by light therapy for brain disorders [14]. The physical  
88 stimulation, therefore, holds great potential for AD or other neurodegenerative  
89 diseases (NDDs).

90 The study employed a special thermal therapy, applied at high and low  
91 temperatures alternately to achieve an effect similar to antioxidant and antiapoptotic  
92 drugs. In our previous study, we used this novel method, thermal cycle hyperthermia  
93 (TC-HT) for the treatment of pancreatic cancer, and found that this physical  
94 stimulation greatly improved the anticancer effect of propolis and polyphenols on  
95 PANC-1 cells without the heat-induced side effect [15, 16]. Traditional HS or HT  
96 employs continuous heating to achieve curative effect, but it is likely to cause neuron  
97 damage since damage to the central nervous system occurs within few minutes of  
98 exposure to 42°C [17]. Nevertheless, the feature of TC-HT is that it can avoid the

99 damage caused by HT, which is crucial for neuroprotection.

100 In this study, we applied the TC-HT strategy to human neural cell line SH-SY5Y,  
101 which has been extensively used in research on neurodegenerative damage in vitro,  
102 and examined the prosurvival effect of TC-HT on preventing oxidative damage  
103 induced by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and A $\beta$ . The results showed that subjection of  
104 the cells to heat at high and low temperatures alternately beforehand ameliorated the  
105 H<sub>2</sub>O<sub>2</sub> and A $\beta$ -induced cytotoxicity in SH-SY5Y cells significantly. It was found that  
106 TC-HT not only performed superior protective effect than the traditional HS but also  
107 avoided thermal damage caused by continuous heating. Examination of the  
108 underlying mechanism also showed that TC-HT could activate specific  
109 neuroprotective proteins. These findings indicate that TC-HT is a promising thermal  
110 therapy, which sheds light on novel treatment for AD or other NDDs.

111

## 112 **Materials and methods**

### 113 **Cell culture and treatment**

114 The human neuroblastoma SH-SY5Y cells purchased from Bioresource Collection  
115 and Research Center (Hsinchu, Taiwan) were maintained in MEM/F-12 mixture  
116 containing 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences) and 1%  
117 penicillin-streptomycin, supplemented with 1mM sodium pyruvate and 0.1 mM

118 non-essential amino acids. The cells were cultured at 37°C in a humidified incubator  
119 composed of 5% CO<sub>2</sub>. SH-SY5Y cells were seeded in 96-well plates overnight. Cells  
120 were pretreated with HT or TC-HT by the Thermal Cycler (Applied Biosystems;  
121 Thermo Fisher Scientific, Inc.) relative to the control at room temperature (RT). After  
122 the treatment, the cells were maintained in a 37°C incubator for 4 h. Subsequently, the  
123 pretreated cells were induced to undergo apoptosis by adding H<sub>2</sub>O<sub>2</sub> to the culture  
124 medium. Cell viability was measured 24 h after the H<sub>2</sub>O<sub>2</sub> treatment. As for AD disease  
125 model, the cells were treated with 25 or 50 μM Aβ<sub>25-35</sub> protein solution. The Aβ stock  
126 solution was prepared by solubilizing the Aβ<sub>25-35</sub> peptide (Sigma-Aldrich; Merck  
127 KGaA) in sterile deionized water to a concentration of 1 mM and then incubated at  
128 37°C for 3 days to allow self-aggregation before treatment. The TC-HT therapy was  
129 applied 4 h before the Aβ treatment for the pretreatment group and 1 h after Aβ  
130 treatment for the post-treatment group, and the cell viability was determined 4 days  
131 after the treatment. For the Akt inhibitor experiment, 12 or 25 μM LY294002 (Cell  
132 Signaling Technology, Inc.) was treated 1 h before the TC-HT.

133

### 134 **Cell Viability Assay**

135 The cell viability was determined by  
136 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich;

137 Merck KGaA) assay. In brief, the culture medium was replaced with MTT solution  
138 (0.5 mg/mL in MEM/F12) and incubated at 37°C for 4 h. Equal volume of the  
139 solubilizing buffer (0.01 M HCl and 10% SDS) was added to dissolve the formazan  
140 crystals. The 96-well plates were analyzed on a FLUOstar OPTIMA microplate reader  
141 (BMG Labtech, Ltd.) at 570 nm, and background absorbance at 690 nm was  
142 subtracted.

143

#### 144 **Lactate dehydrogenase (LDH) assay**

145 The assay measures a stable enzyme LDH, which is released into the cell culture  
146 medium when cell membranes are damaged. LDH levels were measured using a  
147 Cytoscan LDH cytotoxicity assay kit (G-Biosciences; Geno Technology Inc.)  
148 according to the manufacturer's instructions. Briefly, the cells were seeded in 96-well  
149 plates and then incubated with H<sub>2</sub>O<sub>2</sub> with or without thermal cycle pretreatment. For  
150 analysis, 50 µL culture mediums from all wells were transferred to a new 96-well  
151 plate, and 50 µL of reaction mixtures were added to each well and incubated at 37°C  
152 for 20 min. The absorbance was measured at 490 nm using a microplate reader (BMG  
153 Labtech, Ltd.).

154

#### 155 **ROS level detection**



156 ROS levels of cells were detected using the fluorescent dye dihydroethidium (DHE)  
157 (Sigma-Aldrich; Merck KGaA). Cells pretreated with TC-HT or HT at 42.5°C high  
158 temperature setting for 8 cycles or 2 h, respectively, were challenged with H<sub>2</sub>O<sub>2</sub>. After  
159 the treatment of H<sub>2</sub>O<sub>2</sub> for 24 h, cells were washed with PBS, and then incubated with  
160 5 μM DHE dye for 20 min at 37°C in the dark. The fluorescence intensity emitted by  
161 DHE was measured by flow cytometry in the PE channel, and ROS levels were  
162 expressed as mean fluorescence intensity for comparison.

163

### 164 **Mitochondrial membrane potential (MMP) measurement**

165 The MMP was determined by flow cytometry using 3,3'-dihexyloxycarbocyanine  
166 iodide (DiOC<sub>6</sub>(3)) (Enzo Life Sciences International Inc.). DiOC<sub>6</sub>(3) is a lipophilic  
167 cationic fluorescent dye which allows estimation of the percentage of cells with low  
168 MMP. Cells were pretreated with TC-HT or HT 4 h before the H<sub>2</sub>O<sub>2</sub> treatment. After  
169 the treatment of H<sub>2</sub>O<sub>2</sub> for 24 h, cells were harvested and suspended at a density of 1 x  
170 10<sup>6</sup> cells/mL in 1 μM DiOC<sub>6</sub>(3) dye working solution. After incubation at 37°C for 15  
171 min, DiOC<sub>6</sub>(3) intensity was analyzed by flow cytometry in the FITC channel.

172

### 173 **Western blot analysis**

174 The protein expression levels of SH-SY5Y cells were investigated by western blot

175 analysis. Cells treated with TC-HT, HT, or H<sub>2</sub>O<sub>2</sub> were harvested and lysed in RIPA  
176 lysis buffer (EMD Millipore). The cells were harvested within 24 h after H<sub>2</sub>O<sub>2</sub>  
177 treatment, and the timing for different protein collections was adjusted based on  
178 previous literatures [18-20]. For HSP70 and HSP105, cells were lysed 16 h after H<sub>2</sub>O<sub>2</sub>  
179 treatment. For p-Akt, Akt, Nrf2, CREB, IDE, PSMA3, and PSMC3, cells were lysed  
180 15 h after H<sub>2</sub>O<sub>2</sub> treatment. For HO-1, cells were lysed 18 h after H<sub>2</sub>O<sub>2</sub> treatment. After  
181 centrifugation and supernatant collection, equal amounts of proteins were resolved by  
182 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. After drying  
183 for 1 h at RT, the membranes were probed with p-Akt, Akt, Nrf2, p-CREB, PSMA3,  
184 PSMC3 (Cell Signaling Technology, Inc.), HO-1 (Enzo Life Sciences International  
185 Inc.), insulin-degrading enzyme (Abcam) and GAPDH (GeneTex, Inc.) antibodies  
186 overnight at 4°C. The washed membranes were then incubated with horseradish  
187 peroxidase-conjugated goat anti-rabbit secondary antibodies (Jackson  
188 ImmunoResearch Laboratories, Inc.). Immunoreactivity was visualized with an  
189 enhanced chemiluminescence substrate (Advansta, Inc.) and detected with the  
190 Amersham Imager 600 imaging system (GE Healthcare Life Sciences). The images  
191 were analyzed with Image Lab software (Bio-Rad Laboratories, Inc.).

192

## 193 **Statistical analysis**

194 The results were presented as the mean  $\pm$  standard deviation. Statistical analyses using  
195 one-way analysis of variance (ANOVA) followed by Tukey's post-hot test were  
196 performed by OriginPro 2015 software (OriginLab). P-value  $< 0.05$  was considered to  
197 indicate a statistically significant difference.

198

199

## 200 **Results**

### 201 **In vitro-applied TC-HT**

202 We applied the thermal cycle (TC) treatment to SH-SY5Y cells by a modified  
203 polymerase chain reaction (PCR) equipment (Fig 1C). Briefly, in our design, some  
204 protruding parts of the PCR machine and plastic well were milled so that the bottom  
205 of the well can touch the heat sink tightly. The basic TC settings were schemed as Fig  
206 1A, where the temperature was elevated to the desired high temperature and sustained  
207 for a period of time followed by a cooling process at body temperature. It's worth  
208 noting that the adjustment of TC parameters (temperature and time) is based on the  
209 needs and objectives of the experiments. In our experiments, the TC parameters were  
210 set to high temperatures of 42.5°C or 41.5°C for 15 min, then lowered to 37°C and  
211 lasted for 35 sec. This cycle was repeated 8 or 12 times. The HT group maintains the  
212 same high temperature setting throughout the treatment in a continuous manner

213 without a break. To determine the actual temperatures of the cells, a needle  
214 thermocouple located in the bottom of the well was used to monitor the temperatures.  
215 Fig 1B represents the actual temperature measured by the thermocouple every 20 sec.  
216 The actual cycle temperature sensed by the cells was ~42-40.3°C for the setting of  
217 42.5-37°C and ~40.9-39.4°C for 41.5-37°C setting, as shown in Fig 1B.

218

219 **Fig 1. The setup of TC-HT.** (A) Schematic representation of TC parameter settings.  
220 (B) Measurement of the cell temperature during the TC treatment by the  
221 thermocouple. (C) Image of the TC controller setup.

222

## 223 **Effect of TC-HT on H<sub>2</sub>O<sub>2</sub> and A $\beta$ -induced cytotoxicity in** 224 **SH-SY5Y cells**

225 We applied H<sub>2</sub>O<sub>2</sub> to SH-SY5Y cells as an oxidative stress and the cell viability  
226 was assessed by MTT assay. As shown in Fig 2A, treatment of H<sub>2</sub>O<sub>2</sub> on SH-SY5Y  
227 cells for 24 h induced significant decrease of cell viability in a dose-dependent manner.  
228 Treatment of SH-SY5Y cells with 450  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 h reduced the cell viability to  
229 52.9% compared to control cells, which was used in the following experiments. To  
230 investigate whether TC-HT or HT produced protection and increased cell survival  
231 against the oxidative stress induced by H<sub>2</sub>O<sub>2</sub>, the SH-SY5Y cells were pretreated with

232 TC-HT or HT in the experiments. Two high temperature parameters (41.5°C or  
233 42.5°C) were applied for 2 h or 3 h continuously in the HT group, and 8 or 12 cycles  
234 (for 15 min heating time per cycle) in the TC group to make the total thermal doses of  
235 the HT and TC groups equal. After the heat pretreatment, the treated SH-SY5Y cells  
236 were kept in the incubator at 37°C for 4 h. They were then challenged with H<sub>2</sub>O<sub>2</sub> to  
237 generate the oxidative stress, and the cell viability was determined by MTT assay at  
238 24 h after the H<sub>2</sub>O<sub>2</sub> treatment. The results found that H<sub>2</sub>O<sub>2</sub> treatment significantly  
239 reduced the viability of SH-SY5Y cells to 53.7% of the control value, and showed  
240 that the heat pretreatment conferred protective effect and increased the cell viability.  
241 At 41.5°C for 2 h and 8 cycles, HT and TC treatments increased the cell viability to  
242 61.9% and 68.5% of the control value, respectively (Fig 2B). As we increased the  
243 high temperature setting to 42.5°C while maintaining the same heating time, TC  
244 pretreatment greatly increased the cell viability to 83% of the control value under  
245 H<sub>2</sub>O<sub>2</sub> stress, while the HT group only exhibited a slight increase (Fig 2C). When we  
246 further increased the heating time to 3 h, the treatment of HT alone was cytotoxic to  
247 the cells, reducing the cell viability to 75.4%, and the viability was even lower after  
248 the H<sub>2</sub>O<sub>2</sub> treatment (Fig 2C). Interestingly, the TC treatment with the same total  
249 thermal dose (12 cycles) had only a slight influence on the cell viability, and it still  
250 conferred significant neuroprotective effect to the SH-SY5Y cells under H<sub>2</sub>O<sub>2</sub> stress.

251 In particular, the study examined the influence of the cooling process on the  
252 neuroprotective effect. As shown in Fig 2D, for low temperature period longer than 1  
253 min, the TC pretreatment did not produce protective effect to the cells, indicating that  
254 the low temperature period is a critical parameter to be determined for effective  
255 neuroprotection. From molecular point of view, the neuroprotective effect would be  
256 discontinued as long as there were at least one or few critical signalling pathways  
257 being blocked as heating was halted, so we found that the low temperature period  
258 used for effective protection was shorter than the heating time in TC-HT treatment.  
259 On the other hand, the LDH release rate was measured and found to decrease  
260 significantly in the TC pretreatment group compared to the H<sub>2</sub>O<sub>2</sub>-treated group (Fig  
261 2E), further confirming its protective role in maintaining the cell membrane integrity  
262 when cell was under oxidative stress. For AD disease model, A $\beta$  treatment was used  
263 to reduce the viability of SH-SY5Y cells due to the cytotoxicity of the aggregated A $\beta$   
264 (Fig 3A). Our results showed that the TC treatment after A $\beta$  administration greatly  
265 improved the viability of SH-SY5Y cells (Fig 3B) for nearly 25%, indicating the  
266 curative effect of TC in AD disease model in vitro. The most effective high  
267 temperature setting was 42.3°C for 8 cycles in the A $\beta$ -treated cells. The actual high  
268 temperature sensed by the cells was about 41.7°C. Interestingly, the curative effect of  
269 TC pretreatment was less pronounced than that of TC post-treatment (treated after A $\beta$

270 administration), indicating the time point of TC application has great impact on the  
271 curative effect. Moreover, there were no curative effects by both HT pretreatment and  
272 post-treatment on SH-SY5Y cells, whose viability levels were of no difference with  
273 that in the A $\beta$  only group (Fig 3B), implying the toxicity of A $\beta$  was not attenuated by  
274 heat treatment. Thus, the results confirmed the therapeutic effect of TC-HT in AD  
275 disease model in vitro. Furthermore, the light microscopy images showed that the  
276 integrity of the cells was destructed by A $\beta$ , and the TC treatment caused the protective  
277 effect to retain the cell morphology, as shown in Fig 3C.

278 To conclude the result of the H<sub>2</sub>O<sub>2</sub>-induced oxidative stress on SH-SY5Y cells,  
279 the protective effect of TC pretreatment was more pronounced than the HT  
280 preconditioning. And the TC pretreatment at 42.5°C produced much superior  
281 protection effect than at 41.5°C. Noteworthily, the HT pretreatment at 42.5°C for 3 h  
282 decreased the cell viability which indicates that the continuous heating may induce  
283 cell damage. The protective effect of TC was most remarkable at ~42.5°C for 8 cycles.  
284 Therefore, we chose this parameter to evaluate the possible protective mechanism of  
285 TC-HT in the following experiments.

286

287 **Fig 2. Effect of TC-HT on H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in SH-SY5Y cells. (A)**

288 Dose-response curve of SH-SY5Y cells treated with different concentrations of H<sub>2</sub>O<sub>2</sub>

289 for 24 h. (B) SH-SY5Y cells were pretreated at 41.5°C temperature setting and  
290 challenged with or without 450  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . The cell viability was measured by MTT  
291 assay at 24 h after the  $\text{H}_2\text{O}_2$  treatment. (C) SH-SY5Y cells were pretreated at 42.5°C  
292 temperature setting with different thermal dosages and challenged with or without 450  
293  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . The cell viability was measured by MTT assay at 24h after the  $\text{H}_2\text{O}_2$   
294 treatment. (D) Comparison of the neuroprotective effect under different low  
295 temperature period settings. (E) The LDH release was measured to confirm the  
296 neuroprotective effect of TC treatment. SH-SY5Y cells were pretreated at 42.5°C  
297 temperature setting and challenged with or without 450  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . The LDH release  
298 was measured 24h after the  $\text{H}_2\text{O}_2$  treatment. Data represent the mean  $\pm$  standard  
299 deviation (n=3). \*\*\*P < 0.001 and \*\*P < 0.01.

300

301 **Fig 3. Effect of TC-HT on A $\beta$ -induced cytotoxicity in SH-SY5Y cells.** (A) The cell  
302 viability of SH-SY5Y cells treated with 25 or 50  $\mu\text{M}$  A $\beta$  for 4 days. (B) The TC or HT  
303 pretreatment and post-treatment at 42.5°C temperature setting were applied to the  
304 cells before or after 50  $\mu\text{M}$  A $\beta$  administration, and the cell viability was measured by  
305 MTT assay 4 days after treatment. The TC or HT treatment was applied 4 h before the  
306 A $\beta$  administration for the pretreatment group and 1 h after A $\beta$  administration for the  
307 post-treatment group. (C) Representative light microscopy images of SH-SY5Y cells



308 after treatment. The integrity of the cells was destructed by A $\beta$ , and the TC  
309 post-treatment caused the protective effect and retained the cell morphology. Scale bar  
310 = 100  $\mu$ m. Data represent the mean  $\pm$  standard deviation (n=3). \*\*\* P < 0.001.

311

### 312 **TC-HT attenuates H<sub>2</sub>O<sub>2</sub>-induced ROS generation**

313 The onset and progression of AD has been reported to be associated with ROS.  
314 We further studied whether the H<sub>2</sub>O<sub>2</sub>-induced intracellular ROS production could be  
315 attenuated by the TC pretreatment. The intracellular ROS levels were detected using  
316 the fluorescent dye DHE (Fig 4A). Results showed that after exposure to 450  $\mu$ M  
317 H<sub>2</sub>O<sub>2</sub> for 24 h, ROS level was increased to 160% of the control value. When the  
318 SH-SY5Y cells were pretreated with TC-HT, the intracellular ROS level was  
319 significantly ameliorated (Fig 4B). Compared to the TC group, the ROS level was not  
320 changed in the HT group.

321

### 322 **Fig 4. Effect of TC-HT on H<sub>2</sub>O<sub>2</sub>-induced ROS generation in SH-SY5Y cells. (A)**

323 ROS level was measured 24 h after the H<sub>2</sub>O<sub>2</sub> treatment by flow cytometry with DHE  
324 fluorescent dye. (B) Quantification of the ROS levels after H<sub>2</sub>O<sub>2</sub>, TC+H<sub>2</sub>O<sub>2</sub>, or  
325 HT+H<sub>2</sub>O<sub>2</sub> treatment. Data represent the mean  $\pm$  standard deviation (n=3). \*\* P < 0.01.

326

## 327 **TC-HT attenuates MMP loss in H<sub>2</sub>O<sub>2</sub>-treated cells**

328 Many lines of evidence have suggested that mitochondria contribute to  
329 ageing-related neurodegenerative diseases through the accumulation of net cytosolic  
330 ROS production [21]. The levels of MMP are kept relatively stable in healthy cells.  
331 Apoptotic signals are usually initiated by the disruption of normal mitochondrial  
332 function, especially the collapse of MMP. To study the mechanism why H<sub>2</sub>O<sub>2</sub>-induced  
333 apoptosis is alleviated by TC-HT pretreatment, the MMP is further analyzed by the  
334 flow cytometry with DiOC<sub>6</sub>(3) fluorescent dye in the study. As shown in Fig 5A, the  
335 oxidative stress induced by H<sub>2</sub>O<sub>2</sub> caused mitochondrial dysfunction, decreasing the  
336 MMP and therefore decreased the intensity of the DiOC<sub>6</sub>(3) fluorescent signal. From  
337 the quantification results (Fig 5B), it was found that the percentage of cells with  
338 decreased MMP drastically increased after the H<sub>2</sub>O<sub>2</sub> treatment. In contrast to the  
339 group of H<sub>2</sub>O<sub>2</sub> alone, the TC-HT pretreatment noticeably suppressed the  
340 H<sub>2</sub>O<sub>2</sub>-induced dissipation of MMP, so the cells with decreased MMP reduced  
341 significantly, which was attributed to the preservation of the mitochondrial function  
342 and thus caused the blockage of the apoptotic signaling transduction.

343

344 **Fig 5. Effect of TC-HT on H<sub>2</sub>O<sub>2</sub>-induced MMP reduction in SH-SY5Y cells. (A)**

345 MMP was analyzed 24 h after the H<sub>2</sub>O<sub>2</sub> treatment by flow cytometry with DiOC<sub>6</sub>(3)

346 fluorescent dye. (B) Quantification of the cells with decreased MMP after H<sub>2</sub>O<sub>2</sub>,  
347 TC+H<sub>2</sub>O<sub>2</sub>, or HT+H<sub>2</sub>O<sub>2</sub> treatment. Data represent the mean ± standard deviation  
348 (n=3). \*\*\*P < 0.001 and \*\*P < 0.01.

349

## 350 **Effect of heat treatment on heat shock protein (HSP)** 351 **expressions in SH-SY5Y cells**

352 It has been well known that HT triggers expression of HSPs so that cells are able  
353 to protect themselves from stress [22, 23]. To investigate whether the protective effect  
354 of TC-HT was related to the HSPs, we examined the protein expressions of HSP70  
355 and HSP105, both of which were reported to have protective effects. As shown in Fig  
356 6, both HSP expressions were enhanced significantly after HT and TC treatments. The  
357 activation levels of TC, however, was only slightly higher than HT without significant  
358 difference. This phenomenon points out that although TC treatment indeed protects  
359 SH-SY5Y cells more from the oxidative stress of H<sub>2</sub>O<sub>2</sub>, the main mechanism could be  
360 apart from the HSP70 or HSP105. Therefore, other heat-activated stress response  
361 proteins should be considered in the experiments.

362

363 **Fig 6. Effect of TC-HT on expressions of HSPs in SH-SY5Y cells.** (A) Cells were  
364 lysed 16 h after H<sub>2</sub>O<sub>2</sub> treatment and western blot analyses of HSP70 and HSP105

365 expressions were performed. (B) Quantification of HSP70 and HSP105 expressions  
366 after H<sub>2</sub>O<sub>2</sub>, TC+H<sub>2</sub>O<sub>2</sub>, or HT+H<sub>2</sub>O<sub>2</sub> treatment. The expression levels were normalized  
367 to GAPDH. Data represent the mean  $\pm$  standard deviation (n=3). \*\*\* P < 0.001.

368

### 369 **Effect of heat treatment on insulin-degrading enzyme and** 370 **proteasome expressions in SH-SY5Y cells**

371 Insulin-degrading enzyme (IDE) is a highly conserved zinc metallopeptidase  
372 which was originally identified as the key enzyme for the degradation of insulin.  
373 Further studies unraveled its ability to degrade several other polypeptides, including  
374 A $\beta$  [24]. Recent studies demonstrated that IDE was up-regulated in a HSP-like  
375 fashion [25]. In this study, we also examine the expression levels of IDE under the TC  
376 or HT treatment. The results showed that H<sub>2</sub>O<sub>2</sub> significantly decreased the expression  
377 level of IDE and the heat treatment by TC remarkably recovered its expression level  
378 while HT had notably weaker ability to regain the normal condition. Another  
379 important protein quality control system which could degrade the A $\beta$  peptide is the  
380 ubiquitin-proteasome system (UPS). Regulation of A $\beta$  production by the UPS may  
381 have a role in AD pathogenesis and therefore the UPS is regarded as potential  
382 therapeutic target for AD [26]. The proteasome comprises a proteolytic 20S core  
383 particle capped by either one or two 19S regulatory particles. In this study, the protein

384 expression levels of 20S (PSMA3) and 19S (PSMC3) subunits were examined to  
385 verify the effect of thermal treatment on proteasome expression. The results showed  
386 that both expressions of PSMC3 and PSMA3 were weakened by H<sub>2</sub>O<sub>2</sub> significantly.  
387 For the thermal treatment by TC, the levels of PSMC3 and PSMA3 expressions were  
388 greatly recovered especially in the PSMA3 level (return to 80% of the control value).  
389 For the HT treatment group, the degree of recovery was much lower than TC  
390 treatment group in both PSMC3 and PSMA3 expressions, while it had no significant  
391 difference compared to the H<sub>2</sub>O<sub>2</sub>-treated group in PSMA3 protein expressions.

392

393 **Fig 7. Effect of TC-HT on expressions of IDE and proteasome in SH-SY5Y cells.**

394 (A) Cells were lysed 15 h after H<sub>2</sub>O<sub>2</sub> treatment and western blot analyses of IDE and  
395 proteasome subunits (PSMC3 and PSMA3) expressions were performed. (B)  
396 Quantification of IDE, PSMC3, and PSMA3 expressions after H<sub>2</sub>O<sub>2</sub>, TC+H<sub>2</sub>O<sub>2</sub>, or  
397 HT+H<sub>2</sub>O<sub>2</sub> treatment. The expression levels were normalized to GAPDH. Data  
398 represent the mean ± standard deviation (n=3). \*\*\* P < 0.001 and \*\* P < 0.01.

399

400 **Effect of heat treatment on Akt-Nrf2/CREB signalling**  
401 **pathways in H<sub>2</sub>O<sub>2</sub>-treated SH-SY5Y cells**

402 We then examined the signalling pathways that could participate in the

403 neuroprotective mechanism of TC-HT. The Akt pathway is highly conserved in all  
404 cells of higher eukaryotes and plays pivotal roles in cell survival and growth. Once  
405 Akt is activated by phosphorylation, it positively regulates some transcription factors  
406 to allow expression of prosurvival proteins. Therefore, in our study, we examined the  
407 phosphorylation of Akt and the downstream transcription factors including cAMP  
408 response element binding protein (CREB) and nuclear factor erythroid 2-related factor  
409 2 (Nrf2) by western blot analysis. As shown in Fig 8, the expression of  
410 phosphorylated Akt (p-Akt) was increased in H<sub>2</sub>O<sub>2</sub>-treated SH-SY5Y cells compared  
411 to the untreated cells. The increased p-Akt level could be due to the stress response  
412 induced by the oxidative stress of H<sub>2</sub>O<sub>2</sub>. Heat pretreatment further increased the p-Akt  
413 levels in H<sub>2</sub>O<sub>2</sub>-treated SH-SY5Y cells, and the TC group had significantly higher  
414 level of p-Akt than the HT group. We also examined the expression levels of p-CREB  
415 and Nrf2. CREB is an important transcription factor that also triggers expression of  
416 many prosurvival proteins, including Bcl-2 and brain derived neurotrophic factor  
417 (BDNF) [27]. When CREB is phosphorylated, it starts to regulate downstream gene  
418 expression. Besides, Nrf2 is also a key transcription factor that regulates expression of  
419 antioxidant proteins, such as heme oxygenase-1 (HO-1) [28]. As shown in Fig 8, H<sub>2</sub>O<sub>2</sub>  
420 treatment slightly influenced Nrf2 and p-CREB protein expression levels. In the  
421 heat-treated groups, the TC treatment significantly increased the expressions of Nrf2

422 and p-CREB, while the HT treatment increased Nrf2 expression with less significant  
423 level than TC treatment but in turn reduced the expression level of p-CREB. The  
424 HO-1 protein is a heme-containing HSP which is crucial for neuroprotection against  
425 oxidative stress. The result showed that the heat treatment significantly enhanced the  
426 expression levels of HO-1 in TC and HT groups. Particularly, it is worth noting that  
427 the TC treatment had a significant higher level of HO-1 than HT, which could account  
428 for the antioxidant ability of the TC treatment in the ROS experiment.

429

430 **Fig 8. Effect of TC-HT on Akt/Nrf2 and Akt/CREB signalling pathways and**  
431 **related protein expressions.** Cells were lysed 15 h after H<sub>2</sub>O<sub>2</sub> treatment for p-Akt,  
432 Akt, Nrf2, p-CREB proteins, and lysed 18 h after H<sub>2</sub>O<sub>2</sub> treatment for HO-1 protein,  
433 and western blot analyses of p-Akt, Akt, Nrf2, p-CREB, and HO-1 proteins were  
434 performed. Quantification of p-Akt, Nrf2, p-CREB, HO-1 expressions after H<sub>2</sub>O<sub>2</sub>,  
435 TC+H<sub>2</sub>O<sub>2</sub>, or HT+H<sub>2</sub>O<sub>2</sub> treatment. The expression level of p-Akt was normalized to  
436 total Akt while other proteins were normalized to GAPDH. Data represent the mean ±  
437 standard deviation (n=3). \*\*\* P < 0.001, \*\* P < 0.01 and \* P < 0.05.

438

439 **Effect of LY294002 on the TC-HT activated Akt pathway**  
440 **and protective effect**

441 In order to examine if the activation of the Akt pathway was involved in the  
442 neuroprotective effect of TC treatment, we inhibited the phosphoinositide-3-kinase  
443 (PI3K), the upstream kinase of Akt, by the inhibitor LY294002 [29] in the study. In  
444 Fig 9A, we found that H<sub>2</sub>O<sub>2</sub> treatment reduced the viability of SH-SY5Y cells to 58%  
445 of the control value, and TC treatment could greatly increase the cell viability to  
446 ~86% of the control value under H<sub>2</sub>O<sub>2</sub> stress. In the presence of PI3K inhibitor, the  
447 p-Akt level was indeed reversed and the neuroprotective effect of TC treatment  
448 against H<sub>2</sub>O<sub>2</sub>-induced cell apoptosis was abrogated (Fig 9A and 9B), representing that  
449 the Akt pathway was involved to mediate the neuroprotective effect of TC treatment  
450 against H<sub>2</sub>O<sub>2</sub> toxicity. For the downstream proteins of Akt, inhibition of the PI3K/Akt  
451 pathway was found to significantly reduce the induction of Nrf2 by TC treatment,  
452 indicating that the transcription factor Nrf2 was indeed activated by the Akt pathway.  
453 Collectively, these data point out that TC treatment may exhibit neuroprotective effect  
454 via activation of the Akt-Nrf2/CREB signalling pathways in the H<sub>2</sub>O<sub>2</sub>-treated  
455 SH-SY5Y neuron cells.

456

457 **Fig 9. Effect of LY294002 on the neuroprotective effect of TC-HT and related**  
458 **protein expressions.** (A) TC treatment conferred neuroprotective effect and  
459 significantly increased the cell viability of SH-SY5Y neuron cells under the H<sub>2</sub>O<sub>2</sub>



460 stress. The neuroprotective effect of TC treatment was abrogated by addition of the  
461 PI3K inhibitor LY294002 in a dose-dependent manner. (B) Cells were lysed 15 h after  
462 H<sub>2</sub>O<sub>2</sub> or 25 μM LY294002 treatment, and western blot analyses of p-Akt and Nrf2  
463 proteins were performed. The inhibitor LY294002 reversed the activated levels of  
464 p-Akt and Nrf2 induced by TC treatment. The expression level of p-Akt and Nrf2 was  
465 normalized to total Akt and GAPDH, respectively. We used the abbreviation “LY” to  
466 represent the PI3K inhibitor LY294002 in the figure. Data represent the mean ±  
467 standard deviation (n=3). \*\*\*P < 0.001, \*\*P < 0.01 and \*P < 0.05.

468

469

## 470 **Discussion**

471 The study focused on investigating the neuroprotective effect of TC-HT on  
472 SH-SY5Y cells. It showed that subjection of the cells to heat at high and low  
473 temperatures alternately could produce significant protective effect against H<sub>2</sub>O<sub>2</sub> and  
474 Aβ-induced apoptosis in SH-SY5Y human neural cells. The western blot results  
475 showed that TC-HT activated the PI3K/Akt signalling pathway and mediated the  
476 activation of Nrf2 and CREB proteins.

477 A human derived cell line SH-SY5Y has been extensively employed as general  
478 in vitro model in evaluating neuronal damage or neurodegenerative diseases, such as

479 AD and PD [30, 31]. Therefore, the study used SH-SY5Y cells in the experiments to  
480 determine the protective effect of TC-HT against H<sub>2</sub>O<sub>2</sub> and A $\beta$ -induced cytotoxicity.  
481 Although the exact molecular mechanism of neurodegeneration pathogenesis is still  
482 not clear, a common feature of these diseases is oxidative stress [32]. Many  
483 researchers believe that oxidative stress may play a critical role in the etiology and  
484 cause the exacerbation of disease progression. Cellular ROS are generated by both  
485 extrinsic and intrinsic sources, with the former including ultraviolet, drugs, and  
486 environmental toxins. Under normal physiological conditions, ROS generated  
487 intrinsically from mitochondria and other enzymes are maintained at appropriate  
488 levels by endogenous antioxidants. However, when mitochondria suffers from  
489 decreased antioxidant defense or cell inflammation due to damage, excess ROS  
490 production may occur. Since neuron cells are especially vulnerable to oxidative  
491 damage due to their high oxygen demand and high polyunsaturated fatty acid contents  
492 in membranes [33], the imbalance between ROS production and removal may cause  
493 neuron damage or degeneration. A key cellular and molecular mechanism of several  
494 neurodegenerative diseases, such as AD, PD, Huntington's disease (HD), amyotrophic  
495 lateral sclerosis (ALS), is the accumulation of misfolded aggregation proteins in brain  
496 [34]. The deposition of these misfolded protein aggregates can cause inflammation in  
497 brain, inducing significant ROS production and leading to synaptic dysfunction,

498 neuronal apoptosis, and brain degeneration [35]. The composition of protein  
499 aggregates is different among various neurodegenerative diseases. For AD, there are  
500 two main kinds of protein aggregates, namely extracellular amyloid plaques deriving  
501 from amyloid precursor protein and intracellular microtubule-associated protein tau,  
502 known as neurofibrillary tangles [36]. With the complex pathogeneses of A $\beta$  or tau  
503 proteins still remaining largely unknown, several studies have proven that the  
504 accumulation of A $\beta$  increased oxidative stress and led to mitochondrial dysfunction  
505 and DNA/RNA oxidation [37]. Matsuoka et al. showed that AD transgenic mouse  
506 with A $\beta$  accumulation can cause an increase in H<sub>2</sub>O<sub>2</sub> level, suggesting that A $\beta$  may  
507 enhance oxidative stress in AD [38]. The oxidative stress can boost the  
508 hyper-phosphorylation of tau protein and in turn facilitate the aggregation of A $\beta$  [39].  
509 Studies have also pointed out that overexpressed tau proteins make the cells more  
510 vulnerable to oxidative stress [40]. Therefore, efforts have been underway to find  
511 therapeutic strategies that can protect against oxidative stress and alleviate the  
512 symptoms of neurodegenerative diseases. Among numerous ROS species, H<sub>2</sub>O<sub>2</sub> can  
513 be considered to be one of the most important ROS molecules involved in the  
514 progression of AD. Many studies, therefore, used H<sub>2</sub>O<sub>2</sub> to induce oxidative stress in  
515 vitro, as a model in the investigation of the neuroprotective or neurodamage  
516 mechanisms [41-43]. The study also found that H<sub>2</sub>O<sub>2</sub> increased the ROS level in

517 SY-SY5Y cells and caused the cell death in a dose-dependent manner. Additionally,  
518 A $\beta$  was used to further investigate the neuroprotective effect of TC-HT in the AD  
519 disease model. Both MTT and LDH release assays were employed in assessing the  
520 neuroprotective effect of TC-HT. The results showed that TC-HT increased the cell  
521 viability in the H<sub>2</sub>O<sub>2</sub> and A $\beta$ -treated neural cells. The detection of ROS level showed  
522 that one possible mechanism of neuroprotective action of TC-HT exhibited the  
523 antioxidant property, reducing the intracellular ROS level, perhaps due to the increase  
524 of antioxidant enzymes in SH-SY5Y cells, induced by TC-HT. In the western blot  
525 results, the study proved that such effect was through activation of Akt/Nrf2 pathway.

526       The Akt signaling pathway is a key regulator in the survival, proliferation, and  
527 migration of cells, in response to extracellular signals [44]. Phosphorylation of Akt  
528 further activates a set of downstream transcription factors, including Nrf2 and CREB,  
529 which are considered to be mediators of neuroprotection by increasing the expression  
530 of many antioxidant and prosurvival enzymes under oxidative stress. Nrf2 is one of  
531 the most important transcription factors that regulate the expression of various  
532 antioxidant proteins and maintain the redox state in mammalian cells [45, 46]. Among  
533 various antioxidant proteins, HO-1 has been proven to be effective in promoting  
534 antioxidant production and protection against neuronal injury [28]. The study found  
535 that the physical stimulation, TC-HT, could activate the Akt/Nrf2 pathway and

536 upregulate the expression of the antioxidant protein HO-1, thereby reducing the ROS  
537 generation by H<sub>2</sub>O<sub>2</sub>. Compared with the continuous heating of HT group, TC-HT  
538 performed significantly better in activating Akt/Nrf2, HO-1 expression, and ROS  
539 reduction, in agreement with the cell viability assay.

540 Another possible mechanism for neuroprotection of TC-HT may be related to the  
541 activation of Akt/CREB pathway. CREB is the cellular transcription factor activated  
542 by phosphorylation from Akt or other kinases, which triggers expression of  
543 neurotrophins and antiapoptotic proteins. The critical role of CREB in neuronal  
544 plasticity and long-term memory has also been well-documented [47]. In addition to  
545 the neuroprotective effect of CREB by upregulating neurotrophins and antiapoptotic  
546 proteins, recent studies have discovered that CREB also protects neurons via the  
547 antioxidant pathways [27]. The downstream antioxidant genes include HO-1 and  
548 manganese superoxide dismutase (MnSOD). Besides, CREB downregulation is  
549 involved in the pathology of AD [48], and thus increasing the expression of CREB  
550 has been considered a potential therapeutic strategy for AD [49]. In some  
551 preconditioning experiments, CREB seemed to play a key role in the preconditioning  
552 response which protected the cells from the subsequent stress [50]. In the study, it was  
553 observed that TC-HT pretreatment significantly upregulated the activation of CREB  
554 protein, compared with the control group in SH-SY5Y cells. The result further found

555 that HT significantly decreased the expression level of p-CREB compared with the  
556 control cells. The decreased level of p-CREB in HT group indicates that HT may  
557 exert too much heat stress and thus hinder the neuroprotective effect or even cause  
558 damage to the cells. Taken together, the result points out that the neuroprotective  
559 effect of TC-HT could be attributed to the function of antioxidant protein HO-1 or  
560 other prosurvival proteins via activation of Nrf2 and CREB through PI3K/Akt  
561 pathway (Fig 10). Further studies are necessary to identify the specific role of other  
562 downstream neurotrophins and antiapoptotic or antioxidant proteins in the  
563 neuroprotection effect.

564

565 **Fig 10. The proposed mechanisms for the protective effect of TC-HT against**  
566 **H<sub>2</sub>O<sub>2</sub> or A $\beta$ -induced neural injury.** The epidermal growth factor receptor (EGFR) in  
567 the cell membrane could be the upstream receptor sensing extracellular TC-HT  
568 stimulation and transmit the signal to activate the PI3K/Akt pathway, which induces  
569 Nrf2 and CREB activations. The transcription factors entering the nucleus further  
570 enhance the expressions of HO-1 and other prosurvival proteins which decrease the  
571 ROS level and inhibit the apoptosis signal.

572

573 Under stress amid a harsh environment or caused by external stimuli, cells or

574 whole organisms would trigger self-defense systems in response [51]. For example,  
575 fever induced by viral or bacterial infections is a useful defense mechanism capable of  
576 regulating the body temperature, as higher body temperature strengthens immune  
577 cells and increases their ability to kill bacteria and viruses. It also inhibits the growth  
578 of bacteria and viruses, thereby attaining anti-inflammatory effects. Depending on the  
579 intensity and duration of stress, cells would activate cell repair or stress response to  
580 adapt to the new environment or cause their death [52]. The stress response involves  
581 the synthesis of some highly conserved proteins with protective function for cells [53].  
582 For the thermal stress induced when cells or whole organisms are exposed to elevated  
583 temperatures, they would respond by synthesizing an evolutionary highly conserved  
584 family of proteins, known as HSPs [54]. The HS response is a universal phenomenon,  
585 which appears in every tested organism. HSPs are named and classified, according to  
586 their molecular weight. HSP70 (70 kilodaltons in size) is a typical group of HSPs,  
587 which functions a molecular chaperone, to prevent the misfolding of nascent  
588 polypeptide chains and facilitate refolding of misfolded proteins [22]. Many studies  
589 have indicated that HSP70 sub-family is essential in protecting organisms from  
590 various stresses [55]. The study also examined the effect of TC-HT and HT on the  
591 expression of HSP70 and HSP105 [23], both of which have been reported to have  
592 protective effects. The results showed that HT and TC-HT treatments enhanced the

593 expression of both HSPs significantly. However, the activation level of TC-HT was  
594 only slightly higher than HT group, which could not explain the superior protective  
595 effect of TC-HT compared to HT. Another novel HS-like protein, IDE, was identified  
596 as the major A $\beta$  degrading enzyme, and its protein expression level was found to  
597 correlate negatively with the AD pathology [24]. Previous study had shown that IDE  
598 expression was stress-inducible [25]. In the study, it was found that the TC treatment  
599 greatly recovered the H<sub>2</sub>O<sub>2</sub>-induced IDE reduction, and the enhanced level was much  
600 higher than HT treatment. Therefore, IDE could be one of the proteins participating in  
601 the neuroprotective effect under A $\beta$  administration.

602       The stress response enables cells to survive the stress-induced damage. Use of  
603 cells' self-defense ability to adapt the stress environment or manipulation of the stress  
604 response to increase the survival rate may be valuable in regenerative medicine or  
605 disease curing. In fact, there have been examples involving preconditioning of cells  
606 with non-lethal stress to minimize cell damage and improve the transplantation  
607 outcome [56]. While there have been many experiments on thermotolerance and cell  
608 survival [57], none have demonstrated the stress response in neuroprotection and  
609 curation to the best of our knowledge. Besides, the challenge for the manipulation of  
610 cellular stress response is how to fine-tune stress intensity and duration to suit specific  
611 needs and prevent the stress-induced cell damage. The present study demonstrated a



612 delicate and efficient way to activate the stress response, leading to protection and  
613 curation against H<sub>2</sub>O<sub>2</sub> and A $\beta$ -induced cytotoxicity on SH-SY5Y cells. The thermal  
614 dosage was fine-tuned in a heat-and-cold cycling process, to maximize the protective  
615 effect and minimize the heat stress-induced cell damage. Although traditional HS can  
616 activate HSPs which may provide resistance to insults, such as hyperthermia, the  
617 continuous exposure may cause cell damage or even death. Previous studies have  
618 shown that the threshold for thermal damage is different among various tissue cells,  
619 which have different levels of thermal sensibility [58]. For example, the skin cells can  
620 withstand much higher thermal dosage (47°C for 20 min) than neural cells, because  
621 the neural cells are more vulnerable. As the most thermally sensitive tissue, brain can  
622 be damaged by low thermal dosage [58]. To attain optimal thermal dosage for various  
623 tissues, the heating process should be divided into several parts, which is the basic  
624 architecture of TC-HT.

625 In this study, the work presented an efficient and guaranteed way of controlling  
626 the thermal dosage applied to cells. The novelty of the TC-HT strategy is periodically  
627 interspersing the short period of cooling process in the continuous heating HT  
628 treatment. The body temperature (37°C) was selected as the low temperature setting  
629 which mimics the passive cooling process in the human body. Interestingly, our data  
630 demonstrated that the application time of the low temperature period is a critical

631 parameter to determine the efficacy of neuroprotection for TC-HT. For too short  
632 cooling period, the accumulation of the thermal dosage will cause damage to neural  
633 cells like HT. On the other side, it was found that the TC-HT did not produce  
634 protective effect to the cells when low temperature period was longer than 1 min (Fig  
635 2D). It may be due to the reason that the application of too long cooling period (> 1  
636 min) could interrupt the transmission of biochemical signals and protein expressions  
637 stimulated by thermal stress, thus failing to achieve the neuroprotective effect. The  
638 results revealed that 35 sec cooling process at 37°C after 15 min heating at 42.5°C for  
639 8 cycles produces the optimum protective effect to SH-SY5Y cells. This protective  
640 effect employing TC-HT was significantly much better than the continuous HT, which  
641 was due to the activation of other thermal stress-associated proteins apart from HSPs  
642 and the prevention of heat damage. From the LY294002 experiment, it was confirmed  
643 that the superior protective effect resulted partially from the activation of Akt pathway.  
644 One fascinating phenomenon is the antioxidant effect induced by TC-HT, which could  
645 be attributed to the increased antioxidant protein HO-1. Besides, the A $\beta$ -induced  
646 cytotoxicity was also rescued in TC-HT treated cells, which points out the possibility  
647 that some stress-induced proteins might have the ability to eliminate or refold the  
648 aggregated protein or ease the symptom at least. The chaperone or proteasome  
649 systems are possible candidates to be involved in this phenomenon [59]. Actually,

650 previous studies had shown that IDE will interact with 20S proteasome and modulate  
651 its proteolytic activity [60]. Our results showed that TC treatment could not only  
652 enhance the expression of IDE but also increase the proteasome expressions of 20S  
653 (PSMA3) and 19S (PSMC3) subunits. Although the examination was performed for  
654 only one subunit of the 20S and 19S particles, respectively, one could not rule out the  
655 possibility that TC treatment increased the abundance of proteasome complexes.  
656 Further studies are needed to confirm if the proteolytic activity of 20S proteasome is  
657 increased by the TC treatment and thus facilitates the degradation of A $\beta$  polypeptides.

658         It is noteworthy that TC-HT applied after the A $\beta$  administration gives better  
659 curative effect than the pretreatment paradigm, which indicates that TC-HT not only  
660 has the ability to prevent or protect the neurons against the A $\beta$ -induced cytotoxicity  
661 but also could have the potential to cure the disease. The possible explanation for the  
662 superior effect of post-treatment could be that some biochemical signals and elevated  
663 proteins could interact with the A $\beta$  aggregation simultaneously, and these effects  
664 could not maintain until the insult for the pretreated cells. Another advantage is that  
665 the post-treatment paradigms for neuronal injury are also more typical in the clinical  
666 condition. The present study employed PCR equipment to demonstrate the protective  
667 effect of TC-HT in vitro. For in vivo or clinical applications, there are options of other  
668 heating devices, such as high-intensity focused ultrasound (HIFU), which has been

669 widely used as a hyperthermal apparatus [61]. The thermal parameters can also be  
670 fine-tuned by controlling the heating power and the size of heated volume to meet the  
671 specific needs [62].

672 In summary, this is the first study on the manipulation of stress response by  
673 TC-HT, which protects SH-SY5Y human neural cells from H<sub>2</sub>O<sub>2</sub> and A $\beta$ -induced  
674 cytotoxicity. The results confirm that the physical stimulation by TC-HT provides  
675 safer and much superior protective effect than continuous HS. The underlying  
676 molecular mechanism for the protective effect is partially due to the activation of Akt  
677 pathway and the function of some downstream proteins, such as Nrf2, CREB, and  
678 HO-1. Further studies are necessary to confirm the involvement of other  
679 stress-induced proteins activated by TC-HT in the neuroprotective effect or their  
680 ability in degrading or disaggregating the aggregated proteins. It is also advisable for  
681 coupling TC-HT with NDD drugs or natural compounds, in order to attain better  
682 curative effect for NDD patients.

683

## 684 **Funding**

685 This work was supported by grants from Ministry of Science and Technology  
686 (MOST 108-2112-M-002-016 and 105-2112-M-002-006-MY3 to CYC) and Ministry  
687 of Education (MOE 106R880708 to CYC) of the Republic of China. The funders had

688 no role in study design, data collection and analysis, decision to publish, or  
689 preparation of the manuscript.

690

## 691 **Competing Interests**

692 The authors have declared that no competing interests exist.

693

## 694 **Acknowledgments**

695 The authors would like to acknowledge the service provided by the Research  
696 Core Facilities 3 Laboratory of the Department of Medical Research at National  
697 Taiwan University hospital for use of flow cytometry system.

698

## 699 **Author Contributions**

700 **Conceptualization:** Chih-Yu Chao.

701 **Data Curation:** Wei-Ting Chen, Yu-Yi Kuo, Guan-Bo Lin, Chih-Yu Chao.

702 **Formal analysis:** Wei-Ting Chen, Yu-Yi Kuo, Guan-Bo-Lin, Chueh-Hsuan Lu,

703 Hao-Ping Hsu, Yi-Kun Sun, Chih-Yu Chao.

704 **Funding acquisition:** Chih-Yu Chao.

705 **Investigation:** Wei-Ting Chen, Yu-Yi Kuo, Guan-Bo Lin, Chih-Yu Chao.

706 **Project Administration:** Chih-Yu Chao.

707 **Supervision:** Chih-Yu Chao.

708 **Validation:** Wei-Ting Chen, Yu-Yi Kuo, Guan-Bo Lin.

709 **Writing – original draft:** Wei-Ting Chen, Yu-Yi Kuo, Chih-Yu Chao.

710 **Writing – review & editing:** Chih-Yu Chao.

711

## 712 **References:**

- 713 1. Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in  
714 neurodegenerative diseases. *Exp Neurobiol.* 2015; 24:325-340.
- 715 2. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing.  
716 *Nature.* 2000; 408:239-247.
- 717 3. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in  
718 neurodegenerative diseases: from molecular mechanisms to clinical applications.  
719 *Oxidative Med Cell Longev.* 2017; 2017:2525967.
- 720 4. Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer's  
721 disease: the major trends. *Med Res Rev.* 2017; 37:1186-1225.
- 722 5. Alghazwi M, Smid S, Musgrave I, Zhang W. In vitro studies of the  
723 neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta  
724 (A $\beta$ 1-42) toxicity and aggregation. *Neurochem Int.* 2019; 124:215-224.
- 725 6. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular  
726 angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. *J Biol Chem.*  
727 2005; 280:37644-37650.
- 728 7. Yang Y, Zhang X, Ye D, Laforest R, Williamson J, Liu Y, et al. Cavitation dose  
729 painting for focused ultrasound-induced blood-brain barrier disruption. *Sci Rep.* 2019;  
730 9:2840.
- 731 8. Habash RW, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part 1: an  
732 introduction to thermal therapy. *Crit Rev Biomed Eng.* 2006; 34:459-489.
- 733 9. Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of  
734 malignancy by hyperthermia. *Surg Oncol.* 1998; 7:83-90.
- 735 10. Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, et al.  
736 Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA  
737 replication arrest. *Cancer Res.* 2016; 76:2868-2875.
- 738 11. Lord-Fontaine S, Averill-Bates DA. Heat shock inactivates cellular antioxidant

- 739 defenses against hydrogen peroxide: protection by glucose. *Free Radic Biol Med.*  
740 2002; 32:752-765.
- 741 12. Tchouagué M, Grondin M, Glory A, Averill-Bates D. Heat shock induces the  
742 cellular antioxidant defenses peroxiredoxin, glutathione and glucose 6-phosphate  
743 dehydrogenase through Nrf2. *Chem-Biol Interact.* 2019; 310:108717.
- 744 13. Mustafi SB, Chakraborty PK, Dey RS, Raha S. Heat stress upregulates  
745 chaperone heat shock protein 70 and antioxidant manganese superoxide dismutase  
746 through reactive oxygen species (ROS), p38MAPK, and Akt. *Cell Stress Chaperones.*  
747 2009; 14:579-589.
- 748 14. Hamblin MR. Shining light on the head: photobiomodulation for brain disorders.  
749 *BBA clinical.* 2016; 6:113-124.
- 750 15. Chen WT, Sun YK, Lu CH, Chao CY. Thermal cycling as a novel thermal  
751 therapy to synergistically enhance the anticancer effect of propolis on PANC-1 cells.  
752 *Int J Oncol.* 2019; 55:617-628.
- 753 16. Lu CH, Chen WT, Hsieh CH, Kuo YY, Chao CY. Thermal cycling-hyperthermia  
754 in combination with polyphenols, epigallocatechin gallate and chlorogenic acid,  
755 exerts synergistic anticancer effect against human pancreatic cancer PANC-1 cells.  
756 *PLoS One.* 2019; 14:e0217676.
- 757 17. Sminia P, Zee JVD, Wondergem J, Haveman J. Effect of hyperthermia on the  
758 central nervous system: a review. *Int J Hyperthermia.* 1994; 10:1-30.
- 759 18. Son SM, Kang S, Choi H, Mook-Jung I. Statins induce insulin-degrading  
760 enzyme secretion from astrocytes via an autophagy-based unconventional secretory  
761 pathway. *Mol Neurodegener.* 2015; 10:56.
- 762 19. Deane CAS, Brown IR. Induction of heat shock proteins in differentiated human  
763 neuronal cells following co-application of celastrol and arimoclomol. *Cell Stress*  
764 *Chaperones.* 2016; 21:837-848.
- 765 20. Jin X, Xu Z, Cao J, Yan R, Xu R, Ran R, et al. HO-1/EBP interaction alleviates  
766 cholesterol-induced hypoxia through the activation of the AKT and Nrf2/mTOR  
767 pathways and inhibition of carbohydrate metabolism in cardiomyocytes. *Int J Mol*  
768 *Med.* 2017; 39:1409-1420.
- 769 21. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in  
770 neurodegenerative diseases. *Nature.* 2006; 443:787-795.
- 771 22. Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, et al.  
772 The chaperone function of hsp70 is required for protection against stress-induced  
773 apoptosis. *Mol Cell Biol.* 2000; 20:7146-7159.
- 774 23. Hatayama T, Yamagishi N, Minobe E, Sakai K. Role of hsp105 in protection  
775 against stress-induced apoptosis in neuronal PC12 cells. *Biochem Biophys Res*  
776 *Commun.* 2001; 288:528-534.

- 777 24. Tundo GR, Sbardella D, Ciaccio C, Grasso G, Gioia M, Coletta A, et al. Multiple  
778 functions of insulin-degrading enzyme: a metabolic crosslight? *Crit Rev Biochem*  
779 *Mol Biol.* 2017; 52:554-582.
- 780 25. Tundo GR, Sbardella D, Ciaccio C, Bianculli A, Orlandi A, Desimio MG, et al.  
781 Insulin-degrading enzyme (IDE): A novel heat shock-like protein. *J Biol Chem.* 2013;  
782 288:2281-2289.
- 783 26. Gong B, Radulovic M, Figueiredo-Pereira ME, Cardozo C. The  
784 ubiquitin-proteasome system: potential therapeutic targets for Alzheimer's disease and  
785 spinal cord injury. *Front Molec Neurosci.* 2016; 9:4.
- 786 27. Sakamoto K, Karelina K, Obrietan K. CREB: a multifaceted regulator of  
787 neuronal plasticity and protection. *J Neurochem.* 2011; 116:1-9.
- 788 28. Wang Z, Guo S, Wang J, Shen Y, Zhang J, Wu Q. Nrf2/HO-1 mediates the  
789 neuroprotective effect of mangiferin on early brain injury after subarachnoid  
790 hemorrhage by attenuating mitochondria-related apoptosis and neuroinflammation.  
791 *Sci Rep.* 2017; 7:11883.
- 792 29. Sanchezmargalet V, Goldfine ID, Vlahos CJ, Sung CK. Role of  
793 phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor,  
794 LY294002. *Biochem Biophys Res Commun.* 1994; 204:446-452.
- 795 30. Wu X, Kosaraju J, Zhou W, Tam KY. Neuroprotective effect of SLM, a novel  
796 carbazole-based fluorophore, on SH-SY5Y cell model and 3xTg-AD mouse model of  
797 Alzheimer's disease. *ACS Chem Neurosci.* 2017; 8:676-685.
- 798 31. Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease  
799 research: a systematic review. *Mol Neurodegener.* 2017; 12:10.
- 800 32. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative  
801 stress. *Nat Rev Drug Discov.* 2004; 3:205-214.
- 802 33. Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. *Neural*  
803 *Regen Res.* 2012; 7:376-385.
- 804 34. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. *Nat*  
805 *Med.* 2004; 10:S10-S17.
- 806 35. Masters SL, O'Neill LAJ. Disease-associated amyloid and misfolded protein  
807 aggregates activate the inflammasome. *Trends Mol Med.* 2011; 17:276-282.
- 808 36. Choi ML, Gandhi S. Crucial role of protein oligomerization in the pathogenesis  
809 of Alzheimer's and Parkinson's diseases. *FEBS J.* 2018; 285:3631-3644.
- 810 37. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH.  
811 Mitochondria are a direct site of A $\beta$  accumulation in Alzheimer's disease neurons:  
812 implications for free radical generation and oxidative damage in disease progression.  
813 *Hum Mol Genet.* 2006; 15:1437-1449.
- 814 38. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar  $\beta$ -amyloid evokes




- 815 oxidative damage in a transgenic mouse model of Alzheimer's disease. *Neuroscience*.  
816 2001; 104:609-613.
- 817 39. Huang HC, Jiang ZF. Accumulated amyloid- $\beta$  peptide and hyperphosphorylated  
818 tau protein: relationship and links in Alzheimer's disease. *J Alzheimers Dis*. 2009;  
819 16:15-27.
- 820 40. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease.  
821 *Oxidative Med Cell Longev*. 2013; 2013:316523.
- 822 41. de Oliveira MR, de Bittencourt Brasil F, Fürstenau CR. Sulforaphane promotes  
823 mitochondrial protection in SH-SY5Y cells exposed to hydrogen peroxide by an  
824 Nrf2-dependent mechanism. *Mol Neurobiol*. 2017; 55:4777-4787.
- 825 42. Ismail N, Ismail M, Imam MU, Azmi NH, Fathy SF, Foo JB, et al. Mechanistic  
826 basis for protection of differentiated SH-SY5Y cells by oryzanol-rich fraction against  
827 hydrogen peroxide-induced neurotoxicity. *BMC Complement Altern Med*. 2014;  
828 14:467.
- 829 43. Han SM, Kim JM, Park KK, Chang YC, Pak SC. Neuroprotective effects of  
830 melittin on hydrogen peroxide-induced apoptotic cell death in neuroblastoma  
831 SH-SY5Y cells. *BMC Complement Altern Med*. 2014; 14:286.
- 832 44. Jason S, Cui W. Proliferation, survival and metabolism: the role of  
833 PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.  
834 *Development*. 2016; 143:3050-3060.
- 835 45. Huang Y, Li W, Su ZY, Kong ANT. The complexity of the Nrf2 pathway: beyond  
836 the antioxidant response. *J Nutr Biochem*. 2015; 26:1401-1413.
- 837 46. Kubben N, Zhang W, Wang L, Voss TC, Yang J, Qu J, et al. Repression of the  
838 antioxidant NRF2 pathway in premature aging. *Cell*. 2016; 165:1361-1374.
- 839 47. Caracciolo L, Marosi M, Mazzitelli J, Latifi S, Sano Y, Galvan L, et al. CREB  
840 controls cortical circuit plasticity and functional recovery after stroke. *Nat Commun*.  
841 2018; 9:2250.
- 842 48. Rosa E, Fahnestock M. CREB expression mediates amyloid  $\beta$ -induced basal  
843 BDNF downregulation. *Neurobiol Aging*. 2015; 36:2406-2413.
- 844 49. Qin Z. Modulating nitric oxide signaling in the CNS for Alzheimer's disease  
845 therapy. *Future Med Chem*. 2013; 5:1451-1468.
- 846 50. Baranova KA, Rybnikova EA, Churilova AV, Vetrovoy OV, Samoilov MO. The  
847 adaptive role of the CREB and NF- $\kappa$ B neuronal transcription factors in post-stress  
848 psychopathology models in rats. *Neurochem J*. 2014; 8:17-23.
- 849 51. Chovatiya R, Medzhitov R. Stress, Inflammation, and defense of homeostasis.  
850 *Mol Cell*. 2014; 54:281-288.
- 851 52. Thomas MP, Lieberman J. Live or let die: posttranscriptional gene regulation in  
852 cell stress and cell death. *Immunol Rev*. 2013; 253:237-252.


- 853 53. Blanco S, Bandiera R, Popis M, Hussain S, Lombard P, Aleksic J, et al. Stem cell  
854 function and stress response are controlled by protein synthesis. *Nature*. 2016;  
855 534:335-340.
- 856 54. Lindquist S. The heat-shock response. *Annu Rev Biochem*. 1986; 55:1151-1191.
- 857 55. Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG. Antiapoptotic and  
858 anti-inflammatory mechanisms of heat-shock protein protection. *Ann NY Acad Sci*.  
859 2005; 1053:74-83.
- 860 56. Matsumoto K, Honda K, Kobayashi N. Protective effect of heat preconditioning  
861 of rat liver graft resulting in improved transplant survival. *Transplantation*. 2001;  
862 71:862-868.
- 863 57. Mesihovic A, Iannacone R, Firon N, Fragkostefanakis S. Heat stress regimes for  
864 the investigation of pollen thermotolerance in crop plants. *Plant Reprod*. 2016;  
865 29:93-105.
- 866 58. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic  
867 principles of thermal dosimetry and thermal thresholds for tissue damage from  
868 hyperthermia. *Int J Hyperthermia*. 2003; 19:267-294.
- 869 59. Kampinga HH, Bergink S. Heat shock proteins as potential targets for protective  
870 strategies in neurodegeneration. *Lancet Neurol*. 2016; 15:748-759.
- 871 60. Sbardella D, Tundo GR, Coletta A, Marcoux J, Koufogeorgou EI, Ciaccio C, et  
872 al. The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome  
873 and a potential competitor of the 19S. *Cell Mol Life Sci*. 2018; 75:3441-3456.
- 874 61. Frazier N, Payne A, de Bever J, Dillon C, Panda A, Subrahmanyam N, et al.  
875 High intensity focused ultrasound hyperthermia for enhanced macromolecular  
876 delivery. *J Control Release*. 2016; 241:186-193.
- 877 62. Partanen A, Tillander M, Yarmolenko PS, Wood BJ, Dreher MR, Kohler MO.  
878 Reduction of peak acoustic pressure and shaping of heated region by use of multifoci  
879 sonications in MR-guided high-intensity focused ultrasound mediated mild  
880 hyperthermia. *Med Phys*. 2013; 40:013301.

**Figure 1**


**A**




**B**




**C**




**Figure 2**


**Figure 3**





**Figure 4**



**B**




**Figure 5**




**Figure 6**

**A**




**B**






**Figure 7**









**A**



**B**



**Figure 8**





**Figure 9****A****B**

Figure 10

